Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02166463 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

StatusActive, Not Recruiting
PhasePhase 3
Started2015-03-19
View on ClinicalTrials.gov ↗
This phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB with bulk, stage IIIB, IVA, or IVB Hodgkin lymphoma. Combinations of biological substances in brentuximab vedotin may be able to carry cancer-killing substances directly to Hodgkin lymphoma cells. Chemotherapy drugs, such as doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if combination chemotherapy is more effective with or without brentuximab vedotin in treating children with high-risk Hodgkin lymphoma.

Amendment record

Amended 494 times since 2014-06-16; most recent filed 2026-07-07. The 50 most recent of 495 record versions are listed below. See every version on ClinicalTrials.gov ↗

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-07-07
Amendment Study Status, Arms and Interventions v494
2026-06-19
Amendment Study Status v493
2026-06-16
Amendment Study Status, Contacts/Locations v492
2026-06-02
Amendment Study Status, References v491
2026-05-23
Amendment Study Status, Contacts/Locations v490
2026-05-01
Amendment Study Status, Contacts/Locations v489
2026-04-09
Amendment Study Status v488
2026-04-08
Amendment Study Status v487
2026-04-07
Amendment Study Status v486
2026-04-04
Amendment Study Status v485
2026-04-03
Amendment Study Status v484
2026-04-02
Amendment Study Status v483
2026-04-01
Amendment Study Status v482
2026-03-31
Amendment Study Status v481
2026-03-28
Amendment Study Status v480
2026-03-27
Amendment Study Status v479
2026-03-26
Amendment Study Status v478
2026-03-25
Amendment Study Status v477
2026-03-24
Amendment Study Status v476
2026-03-21
Amendment Study Status v475
2026-03-20
Amendment Study Status v474
2026-03-19
Amendment Study Status v473
2026-03-18
Amendment Study Status v472
2026-03-17
Amendment Study Status v471
2026-03-14
Amendment Study Status v470
2026-03-13
Amendment Study Status v469
2026-03-12
Amendment Study Status v468
2026-03-11
Amendment Study Status v467
2026-03-10
Amendment Study Status v466
2026-03-07
Amendment Study Status v465
2026-03-06
Amendment Study Status v464
2026-03-05
Amendment Study Status v463
2026-02-11
Amendment Study Status v462
2025-11-14
Amendment Study Status, Contacts/Locations v461
2025-10-16
Amendment Study Status v460
2025-07-25
Amendment Study Status, Contacts/Locations v459
2025-07-08
Amendment Study Status, Contacts/Locations v458
2025-06-21
Amendment Study Status v457
2025-06-07
Amendment Study Status v456
2025-02-26
Amendment Study Status v455
2025-02-01
Amendment Study Status, Contacts/Locations v454
2024-12-20
Amendment Study Status v453
2024-10-18
Amendment Study Status, Contacts/Locations, References v452
2024-09-28
Amendment Study Status, Contacts/Locations v451
2024-07-12
Amendment Study Status, Arms and Interventions, Contacts/Locations v450
2024-06-26
Amendment Study Status, Contacts/Locations v449
2024-05-31
Amendment Study Status v448
2024-05-18
Amendment Study Status, Contacts/Locations v447
2024-05-16
Amendment Study Status, Contacts/Locations v446
2023-12-01
Amendment Study Status, Arms and Interventions, Contacts/Locations, References v445
Trial Details
NCT Number NCT02166463
Lead Sponsor National Cancer Institute (NCI)
Conditions Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Enrollment 600 participants
Start Date 2015-03-19
Primary Completion 2021-12-31 (estimated)
Study Completion 2026-10-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-29